BD Oncomark™ Anti-Human CD103 FITC/CD22 PE/CD20 PerCP-Cy™5.5
Description
CD103, clone Ber-ACT 8, is derived from hybridization of spleen cells from BALB/c mice immunized with HTLV-1 positive cell line (MAPS16). CD22, clone S-HCL-1, is derived from hybridization of mouse NS-1 myeloma cells with spleen cells from CD-1 mice immunized with whole cells and membrane preparations of hairy-cell leukemia cells. CD20, clone L27, is derived from hybridization of mouse Sp2/0 myeloma cells with spleen cells from BALB/c mice immunized with the LB lymphoblastoid cell line. CD103 recognizes the αE subunit of integrin αEβ7, an integrin also known as the human mucosa lymphocyte (HML) antigen but not α4, another member of the β7 integrin subfamily. Integrin αEβ7 is a trimeric protein complex of three components, 105 kilodaltons (kd) (β7), 150 kd, and 25 kd. The CD103 epitope is localized on the 150-kd chain. CD22 recognizes a human B-lymphocyte antigen, Mr 135 kd. The CD20 antigen is a phosphoprotein with a molecular weight of 35 or 37 kd depending on the degree of phosphorylation. The antigen is not glycosylated.
Preparation And Storage
Store vials at 2–8°C. Do not freeze reagents; protect them from prolonged exposure to light. Each reagent is stable for the period shown on the bottle label when stored as directed.
| Description | Clone | Isotype | EntrezGene ID |
|---|---|---|---|
| N/A | N/A | IgG2b, κ,IgG2a, κ,IgG1, κ | N/A |
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
Although not required, these products are manufactured in accordance with Good Manufacturing Practices.